METHOD FOR MEASURING A PATIENT'S RESPONSE TO HYPOXIE TRAINING

DE502021005665D1Active Publication Date: 2024-11-21GOYTIA RAINER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE502021005665
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-11
Filing Date
2021-12-01
Publication Date
2024-11-21
Estimated Expiration
2041-12-01

AI Technical Summary

Technical Problem

Existing methods for evaluating hypoxia training data provide limited quantitative support, making it difficult to assess patient responses effectively during hypoxia therapy sessions.

Method used

A method involving a normoxic initial phase, a hypoxic phase, and a reoxygenation phase, where oxygen saturation or partial pressure data is plotted to determine a hypoxic session index by comparing deviations from a reference curve, allowing for quantitative assessment through various scores such as Hypoxic Cycle Score, Reoxygenation Max Score, and Dynamic Score.

Benefits of technology

This approach enables a comprehensive, quantitative evaluation of patient responses to hypoxia training, providing actionable insights into oxygen saturation and recovery dynamics, thereby improving the assessment of hypoxia therapy efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

Background of the invention

[0001] The invention relates to a method for measuring a hypoxic session index as a measure of a patient's response to hypoxia training or a hypoxia therapy session, by measuring a parameter that characterizes the peripheral oxygen saturation of the patient's blood and / or the pulse response. Furthermore, a device for carrying out the method is disclosed.

[0002] Methods for conducting a hypoxia therapy session are known from the prior art: DE 10 2012 010 806 A1 discloses a hypoxia therapy session in which a patient's peripheral oxygen saturation and pulse values ​​are sent to a monitoring device while the patient is supplied with a hypoxic gas mixture alternating with a normoxic or hyperoxic gas mixture. The hypoxic gas mixture and the normoxic or hyperoxic gas mixture are each supplied over a predetermined period of time.

[0003] US 2016 / 095994 A1 discloses a method for measuring a hypoxic training index (HTI), wherein a patient is supplied with a hypoxic gas mixture in a hypoxia phase over a predetermined hypoxia period, the patient is supplied with a normoxic gas mixture in a reoxygenation phase over a predetermined hyperoxia period and in a subsequent, predetermined final period, the oxygen saturation is plotted over time in the hypoxia phase and the reoxygenation phase in the form of a data curve, and a hypoxic training index is determined from a deviation of the data curve from a reference value of 90% oxygen saturation.

[0004] The known methods offer comparatively little support in the evaluation of the data obtained during hypoxia training. Object of the invention

[0005] It is therefore an object of the present invention to provide a method in which the data obtained during hypoxia training are evaluated in the form of quantitative results. Brief description of the invention

[0006] This object is achieved according to the invention by a method according to claim 1. Advantageous embodiments emerge from the respective dependent claims.

[0007] The method according to the invention comprises the following steps: I. Supplying the patient with a normoxic gas mixture in an initial phase for a predetermined first period; II. Determining the mean value of the parameter in the initial phase; III. Supplying the patient with a hypoxic gas mixture in a hypoxia phase for a predetermined hypoxia period; IV. Supplying the patient with the normoxic or hyperoxic gas mixture in a reoxygenation phase for a predetermined hyperoxia period and in a subsequent, predetermined final period; V. Plotting the parameter over time in the initial phase, the hypoxia phase and the reoxygenation phase in the form of a data curve; VI.Determining the hypoxic session index from a deviation of the data curve from a predetermined reference curve, wherein the reference curve is a data curve determined according to steps I to V for a reference person, or a data curve calculated by averaging data curves of several reference persons, wherein the data curves are determined according to steps I to V for the reference persons.

[0008] The deviation between the data curve and the reference curve enables a quantitative evaluation of the oxygen saturation measurements. The parameter is, in particular, the oxygen saturation or the partial pressure of the oxygen dissolved in the patient's blood, the relationship between which is represented by the oxygen binding curve with a sigmoidal shape. The deviation is determined, in particular, by the distance between the data curve and the reference curve or by a comparison of areas bounded by the data curve or the reference curve.

[0009] A hypoxia safety value, which in particular indicates the smallest value to which the parameter may fall in the hypoxia phase, is in particular between 70% and 88% of the mean value of the parameter in the initial phase, in particular 80% of the mean value of the parameter in the initial phase.

[0010] During the initial phase, the patient is not physically active and breathes room air. The patient is in a resting position, particularly lying on a couch. During the initial phase, the device for measuring the hypoxic session index is calibrated. The initial phase lasts particularly between 1 minute and 5 minutes. During the initial phase, the parameter, such as the partial pressure of oxygen, is measured and recorded every second, particularly within a period of between 20 seconds and 120 seconds, and particularly 30 seconds, before the start of the first hypoxia phase. After the end of the initial phase, the mean value of the parameter is calculated to determine a baseline for the parameter during hypoxia training. The specified hypoxia period and / or hyperoxia period is particularly between 1 minute and 15 minutes.The determination of the mean value of the parameter in the initial phase according to step II is carried out in particular before the hypoxia phase according to step III, preferably during the initial phase or at the end of the initial phase. In an alternative embodiment of the method, the hypoxia phase according to step III and the hyperoxia phase according to step IV are interchanged. Preferred embodiments of the invention

[0011] A reference person is, in particular, a person who has measured values ​​of the parameter classified as healthy. The reference curve can also be determined by averaging the measured values ​​of the parameter of several reference persons at the same time point in the procedure. If necessary, the reference persons can be subdivided according to their physical characteristics.

[0012] In some embodiments of the method, the Hypoxic Session Index is presented as a list of indices, in particular indices presented in the following text.

[0013] Advantageously, the method is characterized by establishing a Hypoxic Cycle Score (HCS) in the hypoxia phase to determine the Hypoxic Session Index, whereby the following steps are carried out: VII. Establish an HCS reference value of the parameter that is less than the mean value of the parameter in the initial phase and greater than the hypoxia safety value; VIII. Plot the HCS reference value over time in the hypoxia phase as the HCS reference line of the hypoxia phase; IX. Determine an HCS determination area as the area between the data curve and the HCS reference line in the hypoxia phase; X. Determine an HCS reference area as the area between the reference curve and the HCS reference line in the hypoxia phase; XI. Determine an HCS area difference between the HCS reference area and the HCS determination area and / or an HCS area ratio as the ratio of the HCS determination area and the HCS reference area; XII. Determine the value of the hypoxic cycle score as a measure of the HCS area ratio and / or the HCS area difference.

[0014] The HCS is used to compare the decline of the reference curve and the data curve in the hypoxia phase.

[0015] In particular, the HCS reference value is between 88% and 92% of the mean value of the parameter from the initial phase, preferably 90% of the mean value of the parameter from the initial phase.

[0016] In particular, the HCS determination area is defined as the area between the data curve from the time at which the parameter on the data curve has dropped to the HCS reference value to the end time of the hypoxia phase and the HCS reference line from the time at which the parameter has dropped to the HCS reference value to the end time of the hypoxia phase.

[0017] In particular, the HCS reference area is defined as the area between the data curve from the time at which the parameter on the reference line has fallen to the HCS reference value to the end time of the hypoxia phase and the HCS reference line from the time at which the parameter has fallen to the HCS reference value to the end time of the hypoxia phase.

[0018] The Hypoxic Cycle Score (HCS) is determined primarily by the absolute deviation between the HCS determination area and the HCS reference area, which is determined primarily by the HCS area difference. Alternatively, the Hypoxic Cycle Score is determined by the relative deviation between the HCS determination area and the HCS reference area, where the HCS area difference is related to the HCS reference area. The relative deviation is expressed primarily as a percentage.

[0019] A preferred embodiment of the method is characterized by setting a Reoxygenation Max Score (RMS) in the reoxygenation phase to determine the Hypoxic Session Index by the following steps: XIII. Establish an RMS safety time point after the start of the reoxygenation phase; XIV. Determine the RMS safety value of the parameter corresponding to the RMS safety time point on the data curve in the reoxygenation phase; XV. Plot the RMS safety value over time in the reoxygenation phase as the RMS safety line of the reoxygenation phase; XVI. Determine an RMS determination area as the area between the data curve and the RMS safety line in the reoxygenation phase; XVII. Determine an RMS reference area as the area between the reference curve and the RMS safety line in the reoxygenation phase; XVIII. Determine an RMS area difference between the RMS reference area and the RMS determination area and / or an RMS area ratio as the ratio of the RMS determination area and the RMS reference area; XIX. Determine the Reoxygenation-Max Score as a measure of the RMS area ratio and / or the RMS area difference.

[0020] The Reoxygenation-Max Score is used to compare the reference curve with the data curve in the reoxygenation phase.

[0021] The RMS safety time point is preferably 30 seconds to 50 seconds, preferably 45 seconds, after the start of the reoxygenation phase. The RMS safety time point is preferably a time point at which the parameter is between 3% and 10% of the mean value of the parameter from the initial phase.

[0022] In particular, the RMS determination area is defined as the area between the data curve from the RMS safety time point to the end time point of the reoxygenation phase and the RMS safety line from the RMS safety time point to the end time point of the reoxygenation phase.

[0023] In particular, the RMS reference area is defined as the area between the reference curve from the RMS safety time point to the end time point of the reoxygenation phase and the RMS safety line from the RMS safety time point to the end time point of the reoxygenation phase.

[0024] The Reoxygenation Max Score (RMS) is determined primarily by the absolute deviation between the RMS determination area and the RMS reference area, which is determined primarily by the RMS area difference. Alternatively, the Reoxygenation Max Score is determined by the relative deviation between the RMS determination area and the RMS reference area, where the RMS area difference is related to the RMS reference area. The relative deviation is expressed primarily as a percentage.

[0025] In particular, the reference curve rises to 99% of the maximum value of the parameter that the parameter can reach in the initial phase.

[0026] If the parameter is the partial pressure of oxygen or the oxygen saturation, the reference curve rises in particular to 99% of the partial pressure of oxygen or 99% of the oxygen saturation as the maximum healthy value of the parameter, based on the case where all the hemoglobin in the blood is oxygenated. Preferably, the reference curve rises to the maximum healthy value of the parameter within a period of 10 seconds to 14 seconds, preferably 12 seconds, after the RMS safety time.

[0027] A further development of the aforementioned embodiment of the method is characterized by determining a user reoxygenation potential as a measure of the difference between a predetermined reference reoxygenation max score and the reoxygenation max score determined in step XIX. The user reoxygenation potential is, in particular, the aforementioned difference, expressed as a percentage. The reference reoxygenation max score is, in particular, 99% of the maximum value that the parameter can reach in the initial phase.

[0028] Preferred embodiments of the method are characterized by setting a dynamic score in the hypoxia phase to determine the hypoxic session index, comprising the steps: XX. Determining a DS reference time point at which the parameter in the hypoxia phase has decreased to a predefined DS reference value, where the DS reference value is less than the mean value of the parameter in the initial phase and greater than the hypoxia safety value; XXI. Determining the Dynamic Score as a measure of the time difference between the DS reference time point and a predefined DS reference time interval.

[0029] The Dynamic Score is used to indicate the reaction time of a patient's body to a lack of oxygen, measured from the beginning of the hypoxia phase, in particular until a reaction of the body can be measured on a sensor.

[0030] The predetermined DS reference value is in particular 95% to 98%, preferably 97% of the mean value of the parameter from the initial phase. The DS reference time interval is in particular between 40 seconds and 50 seconds, preferably 45 seconds. The time difference between the DS reference time point and the DS reference time interval is recorded as the value of the dynamic score. For negative time difference values ​​and / or time difference values ​​that are greater than a predetermined value, in particular more than 184 seconds, the dynamic score is preferably set to zero. Alternatively or additionally, the measurement time in the initial phase and the hypoxia phase can be divided into time intervals, with each time interval being assigned a hypoxia improvement potential, so that a position of the DS reference time point in a specific time interval corresponds to a specific hypoxia improvement potential.

[0031] Advantageously, the method is characterized by establishing a reoxygenation pulse score in the reoxygenation phase to determine the hypoxic session index, comprising the steps: XXII. Determining an RI reference time point at which the parameter in the reoxygenation phase has increased to a predefined hyperoxia reference value; XXIII. Determining the reoxygenation impulse score as a measure of the time difference between the RI reference time point and a predefined RI reference time interval.

[0032] The reoxygenation impulse score is used to indicate the reaction time of a patient's body to a hyperoxic gas mixture, measured from the beginning of the hyperoxia phase, in particular until a reaction of the body to the hyperoxic gas mixture can be measured by a sensor.

[0033] The specified hyperoxia reference value is in particular 2% to 5%, preferably 3%, of the mean value of the parameter from the initial phase. The RI reference time interval is in particular between 40 and 50 seconds, preferably 45 seconds.

[0034] For negative time difference values ​​and / or time difference values ​​that are greater than a predetermined value, in particular more than 184 seconds, the reoxygenation impulse score is preferably set to zero. Alternatively or additionally, the measurement time in the reoxygenation phase can be divided into time intervals, with each time interval being assigned a reoxygenation improvement potential, so that a position of the RI reference time point in a specific time interval corresponds to a specific reoxygenation improvement potential.

[0035] One embodiment of the method is characterized by establishing an oxygen recovery score in the reoxygenation phase for determining the hypoxic session index by the reoxygenation pulse score and the reoxygenation max score, in particular by averaging.

[0036] The averaging is in particular an arithmetic averaging.

[0037] The oxygen content can be measured using the oxygen partial pressure and / or oxygen saturation. These parameters indicate what percentage of the total hemoglobin in a patient's blood is loaded with oxygen.

[0038] A further embodiment of the method is characterized by the determination of a baseline potential as a measure of the difference between a predetermined ideal value of the oxygen saturation parameter and the mean value of the oxygen saturation parameter from the initial phase. The predetermined ideal value of the oxygen saturation parameter is, in particular, 99% of the maximum value of the parameter that the parameter can achieve in the initial phase.

[0039] An advantageous embodiment of the method is characterized by the definition of a lower limit line and an upper limit line, wherein the lower limit line in the hypoxia phase has smaller values ​​of the parameter than the reference curve and the upper limit line has larger values ​​of the parameter than the reference curve at the same measuring times, wherein the limit lines are determined in particular from measurements of the parameter on one or more test persons, wherein only values ​​of the parameter are taken into account for determining the hypoxic session index which are smaller than the value of the parameter in the upper limit line and larger than the value of the parameter in the lower limit line at the time of measurement of the respective value of the parameter.

[0040] In particular, to calculate the reference areas and determination areas specified in the application, only data points located within the area defined by the reference curves are used. This area is referred to in the application as the hypoxia standard range and defines the range of valid measured values. Parameter values ​​that lie outside the area defined by the boundary line at the respective time are classified as incorrect measured values, for example, due to poor contact between the sensor and the patient. The boundary lines are, in particular, previously measured data curves from test subjects with suitable parameter values ​​for the upper and lower boundary lines.

[0041] A preferred embodiment of the method is characterized by determining the hypoxic session index using a change in the patient's pulse curve during steps III to V. In particular, the increase or decrease in pulse during hypoxia training can be used as an indicator of the body's response to hypoxia training.

[0042] A further development of the above-mentioned embodiment of the method is characterized by determining a heart rate relaxation score by plotting a pulse curve over time during hypoxia training, comprising the following steps: XXIV. Determine the mean pulse value in the initial phase; XXV. Plot the mean pulse value over the duration of the hypoxia training after the initial phase as a heart rate baseline parallel to the time axis, with the heart rate baseline forming a first leg of a relaxation measurement angle; XXVI. Plot a second leg of the relaxation measurement angle, with the second leg passing through the pulse at the start of the hypoxia phase and through the point on the pulse curve with the lowest pulse value after the initial phase; XXVII. Determine the heart rate relaxation score as a measure of the relaxation measurement angle.

[0043] The heart rate baseline is determined, particularly during the initial phase, with the heart rate being measured and recorded every second to determine the heart rate baseline from the average heart rate during the initial phase. The heart rate relaxation score indicates the change in heart rate during hypoxia training. This indicates the patient's relaxation during hypoxia training.

[0044] The maximum heart rate value above the baseline heart rate is used to determine a negative heart rate relaxation score, and the minimum heart rate value below the baseline heart rate is used to determine a positive heart rate relaxation score. In particular, the positive heart rate relaxation score is used to determine the patient's response to hypoxia training.

[0045] One embodiment of the method is characterized by one or more repetitions of steps III to V prior to determining the hypoxic session index according to step VI. During each repetition, particularly referred to as a cycle, one or more of the aforementioned indices can be determined in order to calculate mean values ​​for the respective index or to compare values ​​of the respective indices in order to detect incorrectly measured values ​​within a cycle.

[0046] A device for carrying out a method according to one of the aforementioned embodiments comprises a mask for supplying the hypoxic, normoxic and / or hyperoxic gas mixture to the patient, a controller for controlling the device and a finger clip for measuring the pulse and / or the characteristic variable.

[0047] Such a device allows for the quantitative recording of suitable indices for determining the reaction of a patient’s body.

[0048] One embodiment of the device comprises a mobile application for displaying the hypoxic session index and / or at least one of the indices for determining the hypoxic session index according to one of the aforementioned embodiments. The hypoxic session index can be displayed using colors of a color scale to enable rapid detection of a patient's body's response to hypoxia training. Alternative embodiments of the device comprise a stationary application for displaying the hypoxic session index and / or at least one of the indices for determining the hypoxic session index according to one of the aforementioned embodiments.

[0049] Further advantages of the invention will become apparent from the description and the drawings. Likewise, the features mentioned above and those further described can be used individually or in combination. The embodiments shown and described are not intended to be exhaustive, but rather are exemplary in nature for describing the invention. Detailed description of the invention and drawing

[0050] Fig. 1 schematically shows a device for measuring a patient's response to hypoxia training; Fig. 2 schematically shows an overview of entries measured by the device, through which an indication value, comprising a hypoxic session index and / or a heart rate relaxation score as a measure of a patient's response to hypoxia training, is determined; Fig. 3 schematically shows a method for measuring the hypoxic session index (HSI); Fig. 4 schematically shows a data curve of a parameter recorded in the method; Fig. 5 schematically shows the data curve up to a DS reference time point at which the parameter has dropped to a predetermined DS reference value; Fig. 6 schematically shows a lower boundary line and an upper boundary line of the parameter in a hypoxia phase; Fig.Fig. 7 schematically shows the data curve from the beginning of a reoxygenation phase to an RI reference time at which the parameter has risen to a hyperoxia reference value; Fig. 8 schematically shows the reference curve as well as a first data curve and a second data curve in the reoxygenation phase above an RMS safety value; Fig. 9 schematically shows a patient's pulse plotted in the form of a pulse curve over the measurement time; Fig. 10 schematically shows the device with a display.

[0051] Fig. 1 shows schematically a device 10 for measuring a patient's response to hypoxia training. The device comprises a mask 12 for supplying a hypoxic gas mixture 14, a normoxic and / or hyperoxic gas mixture 16 to a patient (not shown).

[0052] The device also has a control 18for controlling the device 10 and a finger clip 20 and a sensor, arranged in particular in the finger clip 20 22 to measure a pulse RR (see Fig. 9 ) of the patient and / or a parameter KG, which characterizes the oxygen saturation of the patient's blood, for example, the oxygen partial pressure. The device 10 comprises a mobile application 24 to display an indication value 26, which quantifies the patient's body's response to hypoxia training.

[0053] Fig. 2 shows a schematic overview of the entries that determine the value 26. These entries include a hypoxic session index HSI, a hypoxic cycle score HCS, a Reoxygenation-Max Score RMS, a user reoxygenation potential URP, a Dynamic Score DS, a reoxygenation pulse score RIS,an oxygen recovery score ORS, a baseline potential BP, a hypoxia baseline 50a, a heart rate baseline 66, a heart rate relaxation score HRS and / or a heart rate dynamic score HDS. These entries or indices can be displayed in aggregate, for example, as an average, or separately, for example, in list form. In particular, the Hypoxic Session Index (HSI) is derived from one or more of the other aforementioned indices, for example, by averaging these indices.

[0054] Fig. 3 shows a schematic process 100 to measure a patient's response to hypoxia training. In a first step I, the patient is supplied with the normoxic gas mixture 16 in an initial phase, particularly in a resting position. AP (see Fig. 4) over a predetermined first period of time, in particular over a first period of 20 seconds to 40 seconds, preferably 30 seconds. In a second step II, the mean value of the parameter KG in the initial phase AP is calculated. After the initial phase AP, in a third step III, the patient is exposed to a hypoxic gas mixture 14 in a hypoxia phase over a predetermined hypoxia period HP (see Fig. 4 ) until the parameter KG drops to a hypoxia value 82 which is greater than a specified hypoxia safety value 52 is (see Fig. 4 ). In a fourth step IV, the patient (not shown) is treated with a normoxic or hyperoxic gas mixture 16 for a predetermined hyperoxia period in a reoxygenation phase RP (see Fig. 4 ), whereby the parameter KG represents a hyperoxia reference value HRW (see Fig. 4) and in a subsequent, predetermined final period. In a fifth step V, the parameter KG is plotted over time in the initial phase AP, the hypoxia phase HP and the reoxygenation phase RP in the form of a data curve 46 (see Fig. 4 ). In a sixth step VI, the Hypoxic Session Index HSI is calculated from a deviation of the data curve 46 from a predetermined reference curve 48 (see Fig. 4 ) certainly.

[0055] Fig. 4 schematically shows a data curve 46 of the parameter KG, which is recorded in the method 100 for measuring the Hypoxic Session Index 26 over a measurement time MT in the initial phase AP, the hypoxia phase HP, and the reoxygenation phase RP. Also shown is a predetermined reference curve 48 with which the data curve 46 is compared. Hypoxia Baselines 50a the reference curve 48 and 50bof the data curve 46 are obtained by plotting the mean value of measured values ​​of the parameter KG over the measurement time MT in the initial phase AP of the procedure 100. In the reoxygenation phase RP, the reference curve 48 and the data curve 46 rise to the hyperoxia reference value HRW, which is shown schematically here as the same value for the reference curve 48 and the data curve 46. The hyperoxia phase HP begins at the initial time AZP. In the hypoxia phase, the patient is supplied with a hypoxic gas mixture 14 over a predetermined hypoxia period until the parameter KG drops to the hypoxia value 82, which is greater than the predetermined hypoxia safety value 52, which is known as the hypoxia safety value line 52 is plotted over the measurement time MT.

[0056] A predetermined HCS reference value of the parameter KG is smaller than the mean value of the parameter in the initial phase and larger than the hypoxia safety value 52. The HCS reference value is defined as the HCS reference line 54 of the hypoxia phase over the measurement time MT. An HCS determination area 56 is defined as the area between the data curve 46 and the HCS reference line 54 in the hypoxia phase HP. An HCS reference area 58 is determined as the area between the reference curve 48 and the HCS reference line 54 in the hypoxic phase, the end of which is represented by a vertical line. The value of the Hypoxic Cycle Score HCS is defined as a measure of the ratio and / or difference between the HCS determination area 56 and the HCS reference area 58.

[0057] Fig. 5 shows schematically the data curve 46 in the initial phase AP and in the hypoxia phase HP (see Fig. 4 ) up to a DS reference time DRZthe measuring time MT, at which the parameter KG is set to a given DS reference value DBW has fallen. Schematically, the data curve 46 is shown as a straight line in the initial phase AP and up to the point at which it begins to fall.

[0058] The DS reference value DBW is smaller than the mean value of the parameter KG in the initial phase AP and larger than the hypoxia safety value 52 (see Fig. 4). The DS reference value DBW is in particular 96% to 98% of the mean value of the parameter KG from the initial phase AP. The time difference between the DS reference time DRZ and a predetermined DS reference time interval, in particular a DS reference time interval of 40 seconds to 50 seconds, is recorded as the value of the Dynamic Score DS, if necessary divided by a numerical factor, for example 100. In the case of negative values ​​of the time difference and / or values ​​of the time difference that are greater than a predetermined value, in particular more than 184 seconds, the Dynamic Score DS is preferably set to zero.

[0059] Alternatively or additionally, the measurement time in the initial phase AP and the hypoxia phase HP can be divided into time intervals ZIbe divided into groups, whereby each time interval ZI is assigned a hypoxia improvement potential, represented by different hatching in the time intervals ZI, so that a position of the DS reference time DRZ in a certain time interval corresponds to a certain hypoxia improvement potential.

[0060] Fig. 6 shows schematically a lower boundary line 60a and an upper boundary line 60b of the parameter KG in the hypoxia phase HP. The lower boundary line 60a in the hypoxia phase HP shows, at the respective measuring time MT, smaller values ​​of the parameter KG than the reference curve 48 and the upper boundary line 60b shows larger values ​​of the parameter KG than the reference curve 48. Only values ​​of the parameter KG that are in the area limited by the boundary line GFA are, in particular, linked to each other and used to determine the areas and indices mentioned in the application. UG The dashed line marked represents a lower limit of the parameter KG in the hypoxia phase HP, which is used as the hypoxia safety value 52 (see Fig. 4 ) can be selected.

[0061] Fig. 7 shows schematically the data curve 46 from the beginning of the reoxygenation phase RP to an RI reference time RZP the measuring time MT, at which the parameter KG is set to a given hyperoxia reference value HB has increased. Schematically, the data curve 46 is shown as a straight line from the beginning of the reoxygenation phase (RP) to the point at which the parameter BW increases. The hyperoxia reference value (HB) is specifically 2% to 4% of the mean value of the parameter BW from the initial phase (AP).

[0062] The time difference between the RI reference time point RZP and a predetermined RI reference time interval, in particular an RI reference time interval of 40 seconds to 50 seconds, is recorded as the value of the reoxygenation impulse score RIS. For negative time difference values ​​and / or time difference values ​​that are greater than a predetermined value, in particular more than 184 seconds, the reoxygenation impulse score RIS is preferably set to zero. Alternatively or additionally, the measurement time MT in the reoxygenation phase RP can be divided into time intervals ZI, with each time interval ZI being assigned a reoxygenation improvement potential, represented by different shading, so that a position of the RI reference time point RZP in a specific time interval ZI corresponds to a specific reoxygenation improvement potential.

[0063] Fig. 8 shows schematically a reference curve 48 and a first data curve 46aand a second data curve 46b in the reoxygenation phase RP above an RMS safety value RSW, shown over the measuring time MT as a dashed, horizontal RMS safety line RSL. The RMS safety value is a value of the parameter KG on the reference curve 48 at an RMS safety time RSP after the start of the reoxygenation phase RP.

[0064] Here, the first data curve 46a reaches the RMS safety value RSW at an earlier time than the reference curve 48, and the second data curve 46b reaches the RMS safety value RSW at a later time than the reference curve 48. The horizontal line 62 schematically indicates a maximum value of the parameter KG that the reference curve 48, the first data curve 46a, and the second data curve 46b assume in the reoxygenation phase RP in this exemplary embodiment. The cross-hatched area and the coarsely hatched area below the reference curve together form the RMS reference area. RRF. The Reoxygenation-Max Score RMS of the first data curve 46a is calculated as the ratio of the total area of ​​finely hatched area, cross-hatched area and coarsely hatched area below the first data curve as the RMS determination area RBF 1and the RMS reference area RRF. The Reoxygenation-Max Score RMS of the second data curve is determined as the ratio of the roughly hatched area below the second data curve as the RMS determination area RBF 2 and the RMS reference surface RRF.

[0065] The respective user reoxygenation potential URP (see Fig. 2 ) of the first and second data curves is defined as a measure of the difference between a predetermined reference reoxygenation max score, in particular a value between 0.97 and 1, preferably 0.99, and the respective reoxygenation max score RMS of the first and second data curves determined in this way. The respective URP represents a measure of the deviation of the first and second data curves 46a, 46b, respectively, from the reference curve 48 in the reoxygenation phase RP.

[0066] Fig. 9 shows schematically the pulse RR of a patient (not shown) over the measuring time MT in the form of a pulse curve 64.The mean value of the pulse RR in the initial phase AP is used as the heart rate baseline over the duration of the hypoxia training after the initial phase 66 parallel to the time axis of the measurement time MT. The heart rate baseline 66 forms a first leg 68a a relaxation measuring angle RMW. A second leg 68b of the relaxation measuring angle RMW passes through the value of the pulse RR at the initial time AZP a first hypoxia phase HP and through the point 70of the pulse curve 64 with the lowest value of the pulse RR after the initial phase AP. The heart rate relaxation score HRS is defined as a measure of the relaxation measurement angle RMW. In particular, steps II to V of the procedure were repeated several times before determining the heart rate relaxation score, with the hypoxia phases HP, represented by non-hatched areas, and the reoxygenation phases RP, represented by hatched areas, alternating with each other. For each cycle, which includes a hypoxia phase and a subsequent reoxygenation phase, a heart rate dynamic score HDS is determined as the difference between the maximum value of the pulse RR in the cycle, indicated by a horizontal line. 72a, and the minimum value of the pulse RR in the cycle, indicated by a horizontal line 72b, certainly.

[0067] Fig. 10 shows schematically the device 10 with a display 74. The display 74 has a first display field 76ain which the oxygen O 2 supplied to a patient over the measuring time MT is shown as an oxygen curve 78 is shown. In particular, the changing oxygen levels in the hypoxia phase (HP) and the reoxygenation phase (RP) are shown. A hypoxia phase (HP) is always followed by a reoxygenation phase (RP). Also shown are the corresponding values ​​of the parameter that characterizes the oxygen saturation of a patient's blood, in the form of an oxygen partial pressure curve. 80.The left scale of the first display field 76a refers to the oxygen partial pressure SpO2, expressed as a percentage. The right scale refers to the oxygen quantity O2 in the supplied gas mixture, expressed in vol%. The oxygen quantity O2 in the supplied gas mixture fluctuates, in particular, between 7.5 vol% to 17 vol% in the hypoxia phase HP and 20 vol% to 35 vol%, in particular 20.9 vol% to 32 vol%, preferably 25 vol% to 30 vol%, in the reoxygenation phase RP. The horizontal axis indicates the measurement time MT during hypoxia training.

[0068] The display 74 has a second display field 76b in which the values ​​of the oxygen partial pressure SpO2 as the oxygen partial pressure curve 80 and the patient's pulse rate (RR) as the pulse rate curve 64 are plotted over the measurement time (MT). The left scale of the second display field 76b refers to the oxygen partial pressure SpO2, expressed as a percentage. The right scale refers to the pulse rate (RR), expressed in bpm (beats per minute). The horizontal axis indicates the measurement time (MT) during hypoxia training.

[0069] Taking a summary of all the figures of the drawing, the invention relates to a method 100 for measuring a hypoxic session index (HSI) as a measure of a patient's response to hypoxia training, by measuring a parameter (KG) characterizing the oxygen content in the patient's blood. The parameter (KG) is, in particular, the oxygen saturation and / or the partial oxygen pressure (SpO2). The patient is first supplied with a normoxic gas mixture (16) in an initial phase (AP). Subsequently, in a hypoxia phase (HP), the patient is supplied with a hypoxic gas mixture (14) over a predetermined hypoxia period. Subsequently, in a reoxygenation phase (RP), the patient receives a normoxic or hyperoxic gas mixture (16), in particular over a period of 1 minute to 10 minutes.The reoxygenation phase RP extends from the time at which the patient is supplied with the normoxic or hyperoxic gas mixture 16, over a predetermined hyperoxia period, during which the parameter KG reaches a hyperoxia reference value HRW of the parameter KG, and over a subsequent predetermined final period. The Hypoxic Session Index HSI is determined from the differences between a data curve 46, 46a, 46b, comprising the measured values ​​of the parameter KG plotted over the respective measurement time MT, and a predetermined reference curve 48. List of reference symbols

[0070] 10Device 12Mask 14Hypoxic gas mixture 16Normoxic and / or hyperoxic gas mixture 18Control 20Finger clip 22Sensor 24Mobile application 26Specified value 45 Heart Rate Dynamic Score 46, 46a,b Data curve 48 Reference curve 50a,b Hypoxia baselines 52 Hypoxia safety value line 54 HCS reference line 56 HCS determination area 58 HCS reference area 60a, lower, upper boundary line 62 Maximum value of the reference curve and first, second data curve in the reoxygenation phase 64 Pulse curve 66 Heart Rate Baseline 68a,b Leg 70 Point of the pulse curve 64 with the lowest pulse value 72a,b Maximum, minimum pulse value 74 Display 76a,b Display fields 78 Oxygen curve 80 Oxygen partial pressure curve 82Hypoxia value 100 procedures AP Initial phase AZP Starting time of the first hypoxia phase BGF Area limited by the boundary line BP Baseline Potential DBWDS reference value DRZDS reference time DSDynamic Score HB Hyperoxia reference value HCS Hypoxic Cycle Score HDS Heartrate Dynamic Score HP Hypoxia phase HRS Heartrate Relaxation Score HRW Hyperoxia reference value HSI Hypoxic Session Index KG Parameter MT Measurement time ORSOxygen Recovery Score RBFRMS determination area RIS Reoxygenation Pulse Score RMSReoxygenation Max Score RMWRelaxation measurement angle RPR Reoxygenation phase RRPuls RRFRMS reference area RSLRMS safety line RSPRMS safety time RSWRMS safety value RZPRI reference time SBL Hypoxia Baseline (SPO2 baseline) UGLower limit of the parameter in the hypoxia phase URPUser reoxygenation potential ZITime intervals

Claims

1. A method (100) of measuring a hypoxic session index (HSI) as a measure of the response of a patient to hypoxic training, with measurement of an index (KG) that characterizes the oxygen saturation in the patient's blood, having the steps: I. Supplying the patient with a normoxic gas mixture (16) in an initial phase (AP) over a defined first period; II. Determining the mean value of the index (KG) in the initial phase; III. Supplying the patient with a hypoxic gas mixture (14) in a hypoxic phase (HP) over a defined hypoxic period; IV. Supplying the patient with the normoxic or hyperoxic gas mixture (16) in a reoxygenation phase (RP) over a defined hyperoxic period and in a subsequent predetermined concluding period; V. Plotting the index (KG) against time in the initial phase (AP), the hypoxic phase (HP) and the reoxygenation phase (RP) in the form of a data curve (46, 46a, 46b); VI. Determining the hypoxic session index from a difference between the data curve (46, 46a, 46b) and a predetermined reference curve (48), wherein the reference curve (48) is a data curve (46, 46a, 46b) which is determined for a reference person after steps I to V, or a data curve (46, 46a, 46b) which is calculated by averaging data curves (46, 46a, 46b) of a plurality of reference persons, wherein the data curves (46, 46a, 46b) are determined after steps I to V for the reference persons.

2. The method according to claim 1, characterized by setting a hypoxic cycle score (HCS) in the hypoxic phase (HP) for determining the hypoxic session index (HSI) by the following steps: VII. Setting an HCS reference value (54) of the index (KG) that is smaller than the mean value of the index (KG) in the initial phase (AP) and is greater than a hypoxic safety value (52); VIII. Plotting the HCS reference value (54) against time in the hypoxic phase (HP) as an HCS reference line (54) of the hypoxic phase (HP); IX. Determining an HCS determination area (56) as an area between the data curve (46, 46a, 46b) and the HCS reference line (54) in the hypoxic phase (HP); X. Determining an HCS reference area (58) as an area between the reference curve (48) and the HCS reference line (54) in the hypoxic phase (HP); XI. Determining an HCS area difference between the HCS reference area (58) and the HCS determination area (56) and / or an HCS area ratio as the ratio of the HCS determination area (56) and the HCS reference area (58); XII. Determining the value of the hypoxic cycle score (HCS) as a measure of the HCS area ratio and / or the HCS area difference.

3. The method according to any of claims 1 to 2, characterized by setting a reoxygenation max score (RMS) in the reoxygenation phase (RP) for determining the hypoxic session index (HSI) by the following steps: XIII. Setting an RMS safety time (RSP) after the start of the reoxygenation phase (RP); XIV. Determining the RMS safety value (RSW) of the index (KG) associated with the RMS safety time (RSP) on the data curve (46, 46a, 46b) in the reoxygenation phase (RP); XV. Plotting the RMS safety value (RSW) against time (MT) in the reoxygenation phase (RP) as an RMS safety line (RSL) of the reoxygenation phase (RP); XVI. Determining an RMS determination area (RBF1, RBF2) as an area between the data curve (46, 46a, 46b) and the RMS safety line (RSL) in the reoxygenation phase (RP); XVII. Determining an RMS reference area (RRF) as an area between the reference curve (48) and the RMS safety line (RSL) in the reoxygenation phase (RP); XVIII. Determining an RMS area difference between the RMS reference area (RRF) and the RMS determination area (RBF1, RBF2) and / or an RMS area ratio as the ratio of the RMS determination area (RBF1, RBF2) and the RMS reference area (RRF); XIX. Determining the reoxygenation max score (RMS) as a measure of the RMS area ratio and / or the RMS area difference.

4. The method according to claim 3, characterized by determining a user reoxygenation potential (URP) as a measure of the difference between a predetermined reference reoxygenation max score (RMS) and the reoxygenation max score (RMS) determined in step XIX.

5. The method according to any of the preceding claims, characterized by setting a dynamic score (DS) in the hypoxic phase (HP) for determining the hypoxic session index (HSI), having the steps: XX. Determining a DS reference time (DRZ) at which the index (KG) in the hypoxic phase (HP) has dropped to a defined DS reference value (DBW), wherein the DS reference value (DBW) is smaller than the mean value of the index (KG) in the initial phase (AP) and greater than the hypoxic safety value (52); XXI. Determining the dynamic score (DS) as a measure of the time difference between the DS reference time (DRZ) and a defined DS reference time interval.

6. The method according to any of the preceding claims, characterized by setting a reoxygenation impulse score (RIS) in the reoxygenation phase (RP) for determining the hypoxic session index (HSI), having the steps: XXII. Determining an RI reference time (RZP) to which the index (KG) in the reoxygenation phase (RP) has increased to a defined hyperoxic reference value (HB); XXIII. Determining the reoxygenation impulse score (RIS) as a measure of the time difference between the RI reference time (RZP) and a defined RI reference time interval.

7. The method according to any of the preceding claims, characterized by setting an oxygen recovery score (ORS) in the reoxygenation phase (RP) for determining the hypoxic session index (HSI) by the reoxygenation impulse score (RIS) and the reoxygenation max score (RMS), in particular by averaging.

8. The method according to any of the preceding claims, characterized by determining a baseline potential (BP) as a measure of the difference between a predetermined ideal value of the index (KG) of the oxygen saturation and the mean value of the index (KG) of the oxygen saturation from the initial phase (AP).

9. The method according to any of the preceding claims, characterized by setting a lower boundary line (60a) and an upper boundary line (60b), wherein the lower boundary line (60a) in the hypoxic phase (HP) shows smaller values of the index KG than the reference curve (48), and the upper boundary line (60b) shows greater values of the index (KG) than the reference curve (48) at the respective same measurement times, wherein the boundary lines (60a, 60b) are determined, in particular, from measurements of the index (KG) in one or more subjects, wherein only values of the index (KG) are considered for determining the hypoxic session index (HSI), which values are smaller than the value of the index (KG) in the upper boundary line (60b) and greater than the value of the index (KG) in the lower boundary line (60a) at the time of measurement of the respective value of the index (KG).

10. The method according to any of the preceding claims, characterized by determining the hypoxic session index (HSI) by changing a pulse curve (64) of the patient during steps III to V.

11. The method according to claim 10, characterized by determining a heart rate relaxation score (HRS) by plotting a pulse curve (64) against time during hypoxic training, having the following steps: XXIV. Determining the mean value of the pulse (RR) in the initial phase (AP); XXV. Plotting the mean of the pulse (RR) against the duration of the hypoxic training after the initial phase (AP) as a heart rate baseline (66) parallel to the time axis, wherein the heart rate baseline (66) forms a first leg (68a) of a relaxation measurement angle (RMW); XXVI. Plotting a second leg (68b) of the relaxation measurement angle (RMW), wherein the second leg (68b) runs through the pulse (RR) at the start time (AZP) of the hypoxic phase (HP) and through the point (70) of the pulse curve (64) having the lowest value of the pulse (RR) after the initial phase (AP); XXVII. Determining the heart rate relaxation score (HRS) as a measure of the relaxation measurement angle (RMW).

12. The method according to any of the preceding claims, characterized by one or more repetitions of steps III to V before determining the hypoxic session index (HSI) according to step VI.